Raymond James analyst Danielle Brill reinstates Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and announces $51 price target.
Raymond James Reinstates Outperform on Agios Pharmaceuticals, Announces $51 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.